Patents by Inventor Jason Robert Pinckney

Jason Robert Pinckney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF
    Publication number: 20220220220
    Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 14, 2022
    Inventors: Joseph M. Luettgen, Lumelle Schneeweis, Ginger Chao Rakestraw, Christina Terragni, Andrew Karl Dilger, Jason Robert Pinckney, Steven Sheriff, Kevin Kish, Yongmi An, William R. Ewing, Stanley Richard Krystek, JR., Aaron Paul Yamniuk
  • ANTI-CXCR3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190119391
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 25, 2019
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • ANTI-CXCR3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180086838
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 29, 2018
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Nucleic acids encoding anti-CXCR3 antibodies
    Patent number: 9765144
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: September 19, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • ANTI-CXCR3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140377806
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Anti-CXCR3 antibodies and methods of use thereof
    Patent number: 8865870
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: October 21, 2014
    Assignee: Genzyme Corporation
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • ANTI-CXCR3 ANTIBODIES
    Publication number: 20130251733
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: January 18, 2013
    Publication date: September 26, 2013
    Applicant: Genzyme Corporation
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu